HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice

Biochemical and Biophysical Research Communications

Volumn 314, Issue 3, 2004, Pages 781-786

  Acosta Rivero, Nelson ^a   Dueñas Carrera, Santiago ^a   Alvarez Lajonchere, Liz ^a   Morales Grillo, Juan ^a  

^a NONE

Author keywords

Core antigen; CTL response; DNA immunization; Hepatitis C

Indexed keywords

CORE PROTEIN; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CHEMICAL REACTION; CONTROLLED STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DELAYED HYPERSENSITIVITY; DNA DETERMINATION; EDEMA; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; GENE VECTOR; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IATROGENIC DISEASE; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

HEPATITIS C VIRUS;

EID: 1642578976     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.168     Document Type: Article

References (18)

1. Cohen J. The scientific challenge of Hepatitis C virus. Science. 285:1999;26-30.
2. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon-α2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: hepatitis interventional therapy group. N. Engl. J. Med. 339:1998;1485.
3. Kundig T.M., Bachmann M.F., Oehen S., Hoffmann U.W., Simard J.J.L., Kalberer C.P., Pircher H., Ohashi P.S., Hengartner H., Zinkernagel R.M. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. USA. 93:1996;9716-9723.
4. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449.
5. + T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181:2000;1528-1536.
6. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
7. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., Lau J.Y. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology. 28:1998;225-230.
8. Dueñas-Carrera S., Alvarez-Lajonchere L., Alvarez-Obregón J.C., Herrera A., Lorenzo L.J., Pichardo D., Morales J. A truncated variant of the hepatitis C virus core induces a slow but potent immune response in mice following DNA immunization. Vaccine. 19:2000;992-997.
9. Shirai M., Okada H., Nishioka M., Akatsuka T., Wychowski C., Houghten R., Pendleton C.D., Feinstone S.M., Berzofsky J.A. An epitope in Hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J. Virol. 68:1994;3334-3342.
10. b-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc. Natl. Acad. Sci. USA. 92:1995;2479-2483.
11. J. Morales, A. Viña, C. Garcia, N. Acosta-Rivero, S. Dueñas-Carrera, O. Garcia, I. Guerra, V. Falcon, 1998, Sequences derived from the genome of the hepatitis C virus, and use thereof, WO 98/25960.
12. Houghten R.A., DeGraw S.T., Bray M.K., Hoffmann S.R., Frizzell N.D. Simultaneous multiple peptide synthesis: the rapid preparation of large numbers of discrete peptides for biological, immunological, and methodological studies. Biotechniques. 4:1986;522-526.
13. N2 deprotection of synthetic peptides with a low concentration of HF in dimethyl sulfide: evidence and application in peptide synthesis. J. Am. Chem. Soc. 105:1983;6442-6455.
14. Horn N.A., Meek J.A., Budahazi G., Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther. 6:1995;565-573.
15. Dueñas-Carrera S., Alvarez-Lajonchere L., Alvarez-Obregón J.C., Pérez A., Acosta-Rivero N., Vázquez D.M., Martínez G., Viña A., Pichardo D., Morales J. Enhancement of the immune response generated against the hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol. Appl. Biochem. 35:2002;205-212.
16. Kundig T.M., Althage A., Hengartner H., Zinkernagel R.M. Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. USA. 89:1992;7757-7761.
17. Lemieux P. Technological advances to increase immunogenicity of DNA vaccines. Expert Rev. Vaccines. 1:2000;85-93.
18. + T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12):2003;1645- 1655.